Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin L Maughan

Showing results (81-90 of 111) with videos related to

Pageof 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2024
Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 StudyTobias Else, Eric Jonasch, Othon Iliopoulos, et al.
The Prostate|August 2, 2017
The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancerLauren C Harshman, Lillian Werner, Abhishek Tripathi, et al.
Journal of Kidney Cancer and VHL|April 30, 2025
First-Line Ipilimumab with Nivolumab versus Immune Checkpoint Inhibitors with Tyrosine Kinase Inhibitors in Patients with Intermediate- or Poor-Risk Metastatic Clear Cell Renal Cell CarcinomaMicah Ostrowski, Yeonjung Jo, Georges Gebrael, et al.
JAMA Network Open|March 20, 2025
Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the USZeynep Irem Ozay, Yeonjung Jo, Gliceida Galarza Fortuna, et al.
JAMA Network Open|June 24, 2026
Bone-Modifying Agents in Metastatic Castration-Resistant Prostate CancerZeynep Irem Ozay, Yeonjung Jo, Georges Gebrael, et al.
The New England Journal of Medicine|November 24, 2021
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau DiseaseEric Jonasch, Frede Donskov, Othon Iliopoulos, et al.
Cancer|April 2, 2024
Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitorGeorges Gebrael, Yeonjung Jo, Vinay Mathew Thomas, et al.
European Urology Focus|April 5, 2024
Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor-based CombinationsGeorges Gebrael, Luis Meza, Xiaochen Li, et al.
JAMA Network Open|April 7, 2026
Trends and Disparities in the Use of Next-Generation Sequencing in Patients With Cancer in the United StatesChadi Hage Chehade, Zeynep Irem Ozay, Yeonjung Jo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2017
Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and EnzalutamideEmmanuel S Antonarakis, Changxue Lu, Brandon Luber, et al.
Pageof 12

Showing results (81-90 of 111) with videos related to

Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2024
Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 StudyTobias Else, Eric Jonasch, Othon Iliopoulos, et al.
The Prostate|August 2, 2017
The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancerLauren C Harshman, Lillian Werner, Abhishek Tripathi, et al.
Journal of Kidney Cancer and VHL|April 30, 2025
First-Line Ipilimumab with Nivolumab versus Immune Checkpoint Inhibitors with Tyrosine Kinase Inhibitors in Patients with Intermediate- or Poor-Risk Metastatic Clear Cell Renal Cell CarcinomaMicah Ostrowski, Yeonjung Jo, Georges Gebrael, et al.
JAMA Network Open|March 20, 2025
Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the USZeynep Irem Ozay, Yeonjung Jo, Gliceida Galarza Fortuna, et al.
JAMA Network Open|June 24, 2026
Bone-Modifying Agents in Metastatic Castration-Resistant Prostate CancerZeynep Irem Ozay, Yeonjung Jo, Georges Gebrael, et al.
The New England Journal of Medicine|November 24, 2021
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau DiseaseEric Jonasch, Frede Donskov, Othon Iliopoulos, et al.
Cancer|April 2, 2024
Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitorGeorges Gebrael, Yeonjung Jo, Vinay Mathew Thomas, et al.
European Urology Focus|April 5, 2024
Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor-based CombinationsGeorges Gebrael, Luis Meza, Xiaochen Li, et al.
JAMA Network Open|April 7, 2026
Trends and Disparities in the Use of Next-Generation Sequencing in Patients With Cancer in the United StatesChadi Hage Chehade, Zeynep Irem Ozay, Yeonjung Jo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2017
Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and EnzalutamideEmmanuel S Antonarakis, Changxue Lu, Brandon Luber, et al.
Pageof 12